Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 163

Sort by

Sort Order Select

Journal Articles

LEF1 intragenic deletion induces a dominant-negative isoform and unveils a Wnt/β-catenin vulnerability in T-ALL

Manon Delafoy, Mickaël F. Bonnet, Etienne Lengliné, Agata Cieslak, Aurore Touzart, Estelle Balducci, Mathieu Simonin, Véronique Lhéritier, Marie Emilie Dourthe, Benoît Heid-Picard, Sylvain Latour, Hervé Dombret, Philippe Rousselot, André Baruchel, Nicolas Boissel, Guillaume P. Andrieu, Vahid Asnafi

Blood (2025) 146 (25): 3036–3049.

https://doi.org/10.1182/blood.2025030161

Published: 2025

Includes: Supplemental data

Journal Articles

Blinatumomab consolidation in high-risk Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia in adults: Final report of the graall-2014/b-QUEST study.

Blood (2025) 146 (Supplement 1): 643.

https://doi.org/10.1182/blood-2025-643

Published: 2025

Journal Articles

Phase 1/2 study of MP0533, a tetra-specific T cell engager (CD33 x CD123 x CD70 x CD3), in patients with relapsed/refractory AML or MDS/AML: Initial results from optimized treatment regimen including densified MP0533 dosing and adapted premedication

Pierre Bories, Mojca Jongen-Lavrencic, Laimonas Griškevičius, Thomas Pabst, David de Leeuw, Gerwin A. Huls, Nicolas Boissel, Arnaud Pigneux, Steffen Boettcher, Mariola Dymkowska, Christiane Andrieu, Elena Fernandez, Paul Baverel, Vaia Stavropoulou, Michael Sanderson, Vladimir Kirkin, Philippe Legenne, Marion Subklewe

Blood (2025) 146 (Supplement 1): 3419.

https://doi.org/10.1182/blood-2025-3419

Published: 2025

Journal Articles

Increased alemtuzumab exposure correlates with improved responses in heavily pretreated R/R ALL patients: Analysis of the balli-01 trial

Nitin Jain, Nicolas Boissel, Daniel Deangelo, Aravind Ramakrishnan, Laurent Poirot, Xenia Naj, Carolyn Figliola, Adrian Kilcoyne

Blood (2025) 146 (Supplement 1): 5952.

https://doi.org/10.1182/blood-2025-5952

Published: 2025

Journal Articles

Outcome after relapse in older patients with Philadelphia Chromosome–Negative B-cell ALL treated with inotuzumab ozogamicin and low-dose chemotherapy in first-line therapy: A graall study

Blood (2025) 146 (Supplement 1): 3340.

https://doi.org/10.1182/blood-2025-3340

Published: 2025

Journal Articles

Integrating palliative care for adolescents and young adults with hematologic malignancies: Insights from a dedicated french unit.

Agathe Picard, Victoria Hadida, Matthieu Jestin, Candice Cavalie, Audrey Lebel, Rachelle Chamoux, Lucille Gros, Abdelaziz Darrazi, nadia Ahamada, Aude-Marie Fourmont, Victoire De Marcellus, Loïc Vasseur, Florence Rabian, Nathalie Dhedin, Nicolas Boissel, Florian Chevillon

Blood (2025) 146 (Supplement 1): 4618.

https://doi.org/10.1182/blood-2025-4618

Published: 2025

Journal Articles

Phase 1 evaluation of the safety and efficacy of rapcabtagene autoleucel (YTB323) in adult patients with Relapsed/Refractory B-cell acute lymphoblastic leukemia (r/r B-ALL)

Blood (2025) 146 (Supplement 1): 811.

https://doi.org/10.1182/blood-2025-811

Published: 2025

Journal Articles

Outcomes of NPM1-mutated AMLs in first hematological relapse and prognostic value of MRD

Blood (2025) 146 (Supplement 1): 5294.

https://doi.org/10.1182/blood-2025-5294

Published: 2025

Journal Articles

Therapy-related core binding factor Acute Myeloid Leukemia – a Study of the french acute leukemia intergroup

Blood (2025) 146 (Supplement 1): 37.

https://doi.org/10.1182/blood-2025-37

Published: 2025

Journal Articles

Age‐adapted chemotherapy and MRD‐oriented transplant for Ph-negative acute lymphoblastic leukemia: the GRAALL-2014 trial

Blood blood.2025029611.

https://doi.org/10.1182/blood.2025029611

Published: 2025

Includes: Supplemental data

Journal Articles

Phase 1/2 trial of anti-CD7 allogeneic WU-CART-007 for patients with relapsed/refractory T-cell malignancies

Blood (2025) 146 (10): 1163–1173.

https://doi.org/10.1182/blood.2025028387

Published: 2025

Includes: Supplemental data

Journal Articles

Project EVOLVE: an international analysis of postimmunotherapy lineage switch, an emergent form of relapse in leukemia

Sara K. Silbert, Alexander W. Rankin, Chloe N. Hoang, Alexandra Semchenkova, Regina M. Myers, Elena Zerkalenkova, Hao-Wei Wang, Alexandra E. Kovach, Constance M. Yuan, Dana Delgado Colon, Loïc Vasseur, Alex Bataller, Samuel John, Kaylyn Utley Lyons, Barbara Friedes, Anna Alonso-Saladrigues, Hisham Abdel-Azim, Estelle Balducci, Ahmed Assim Aljudi, Marie Balsat, D. Nathan Biery, Aghiad Chamdin, Bill H. Chang, Raymund S. Cuevo, Barbara De Moerloose, David S. Dickens, Ulrich Duffner, Nicolas Duployez, Firas El Chaer, Michelle Ann Elliott, Gabriele Escherich, Sneha Fernandes, Mandi R. Fitzjohn, Zhubin Gahvari, Stephan A. Grupp, Rui Rochelle He, Cynthia Harrison, Christopher B. Hergott, Emily M. Hsieh, Annette S. Kim, Dennis J. Kuo, Daniel P. Larson, Benjamin J. Lee, Thibaut Leguay, R. Coleman Lindsley, Abhishek A. Mangaonkar, Kerstin Mezger, Holly L. Pacenta, Jing Pan, Marlie Provost, Latika Puri, Sunil S. Raikar, Armando Martinez, Isabella Bristol, Kyle Murphy, Lauren Reiman, Michele Redell, Kelly Reed, Gabrielle Roth-Guepin, Jeremy Rubinstein, Süreyya Savaşan, Kristian Schafernak, Alexandra Stevens, Aimee Talleur, Naomi Torres Carapia, Jacques Vargaftig, Anant Vatsayan, Matthias Wölfl, Liping Zhao, Susana Rives, Vanessa A. Fabrizio, Koji Sasaki, Ibrahim Aldoss, Nicolas Boissel, Susan R. Rheingold, Kara L. Davis, Sara Ghorashian, Elad Jacoby, Alexander Popov, Adam J. Lamble, Nirali N. Shah

Blood (2025) 146 (4): 437–455.

https://doi.org/10.1182/blood.2024026655

Published: 2025

Includes: Supplemental data

Journal Articles

Surface pTα expression predicts LCK activation and preclinical synergy of LCK and JAK coinhibition in adult T-ALL

Blood (2025) 145 (24): 2903–2913.

https://doi.org/10.1182/blood.2024027982

Published: 2025

Includes: Supplemental data

Journal Articles

Resolve AML 001: An Adaptive Open-Label Multicentre Phase 1/2 Trial, to Determine the Recommended Phase 2 Dose of Cctx-001, and to Assess Safety, Tolerability, and Clinical Activity in Patients with r/r AML

Marion Subklewe, Nicolas Boissel, Stephan Mielke, Pere Barba, Elisa Sala, Eric Deconinck, Olivia Fiere, Jonathan Jaeger, Chloe Vasseghi, Marina Deschamps, Christophe Ferrand, Edouard De Dreuzy, Richard Sainson, Jens Hasskarl

Blood (2024) 144 (Supplement 1): 2883.2.

https://doi.org/10.1182/blood-2024-203204

Published: 2024

Journal Articles

IL-1RAP Is a Targetable Surface Antigen in Relapsed/Refractoy AML

Blood (2024) 144 (Supplement 1): 4311.

https://doi.org/10.1182/blood-2024-199673

Published: 2024

Journal Articles

How to Administer Pegaspargase during Induction Treatment of Acute Lymphoblastic Leukemia in Children and Adolescents? Results of the Caall-F01, a Multicentre Randomized Clinical Trial from the French Pediatric Cancer Society (SFCE)

Blood (2024) 144 (Supplement 1): 2814.

https://doi.org/10.1182/blood-2024-205327

Published: 2024

Journal Articles

Switch of Asparaginase Formulation Based on Antibody Monitoring in Adults with Philadelphia-Negative Adult Lymphoblastic Leukemia. Results of the Graall-2014 Trial

Blood (2024) 144 (Supplement 1): 1434.

https://doi.org/10.1182/blood-2024-199110

Published: 2024

Journal Articles

Characteristics and Outcome Determinants in Children, Adolescents and Young Adults Who Failed Tisagenlecleucel for B-Cell Acute Lymphoblastic Leukemia

Blood (2024) 144 (Supplement 1): 1433.

https://doi.org/10.1182/blood-2024-209895

Published: 2024

Journal Articles

Handling of Allograft As an Intercurrent Event in Randomized Controlled Trials in Acute Leukemias: A Systematic Review

Roxane Couturier, Loic Vasseur, Nicolas Boissel, Hervé Dombret, Sylvie Chevret, Jérôme Lambert

Blood (2024) 144 (Supplement 1): 7449.

https://doi.org/10.1182/blood-2024-194149

Published: 2024

Journal Articles

MP0533 (CD33 x CD123 x CD70 x CD3), a Tetra-Specific CD3-Engaging Darpin for the Treatment of Patients with Relapsed/Refractory AML or MDS/AML: Results of an Ongoing Phase 1/2a Study

Blood (2024) 144 (Supplement 1): 2881.

https://doi.org/10.1182/blood-2024-199211

Published: 2024

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

LEF1 intragenic deletion induces a dominant-negative isoform and unveils a Wnt/β-catenin vulnerability in T-ALL

Blinatumomab consolidation in high-risk Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia in adults: Final report of the graall-2014/b-QUEST study.

Phase 1/2 study of MP0533, a tetra-specific T cell engager (CD33 x CD123 x CD70 x CD3), in patients with relapsed/refractory AML or MDS/AML: Initial results from optimized treatment regimen including densified MP0533 dosing and adapted premedication

Increased alemtuzumab exposure correlates with improved responses in heavily pretreated R/R ALL patients: Analysis of the balli-01 trial

Outcome after relapse in older patients with Philadelphia Chromosome–Negative B-cell ALL treated with inotuzumab ozogamicin and low-dose chemotherapy in first-line therapy: A graall study

Integrating palliative care for adolescents and young adults with hematologic malignancies: Insights from a dedicated french unit.

Phase 1 evaluation of the safety and efficacy of rapcabtagene autoleucel (YTB323) in adult patients with Relapsed/Refractory B-cell acute lymphoblastic leukemia (r/r B-ALL)

Outcomes of NPM1-mutated AMLs in first hematological relapse and prognostic value of MRD

Therapy-related core binding factor Acute Myeloid Leukemia – a Study of the french acute leukemia intergroup

Age‐adapted chemotherapy and MRD‐oriented transplant for Ph-negative acute lymphoblastic leukemia: the GRAALL-2014 trial

Phase 1/2 trial of anti-CD7 allogeneic WU-CART-007 for patients with relapsed/refractory T-cell malignancies

Project EVOLVE: an international analysis of postimmunotherapy lineage switch, an emergent form of relapse in leukemia

Surface pTα expression predicts LCK activation and preclinical synergy of LCK and JAK coinhibition in adult T-ALL

Resolve AML 001: An Adaptive Open-Label Multicentre Phase 1/2 Trial, to Determine the Recommended Phase 2 Dose of Cctx-001, and to Assess Safety, Tolerability, and Clinical Activity in Patients with r/r AML

IL-1RAP Is a Targetable Surface Antigen in Relapsed/Refractoy AML

How to Administer Pegaspargase during Induction Treatment of Acute Lymphoblastic Leukemia in Children and Adolescents? Results of the Caall-F01, a Multicentre Randomized Clinical Trial from the French Pediatric Cancer Society (SFCE)

Switch of Asparaginase Formulation Based on Antibody Monitoring in Adults with Philadelphia-Negative Adult Lymphoblastic Leukemia. Results of the Graall-2014 Trial

Characteristics and Outcome Determinants in Children, Adolescents and Young Adults Who Failed Tisagenlecleucel for B-Cell Acute Lymphoblastic Leukemia

Handling of Allograft As an Intercurrent Event in Randomized Controlled Trials in Acute Leukemias: A Systematic Review

MP0533 (CD33 x CD123 x CD70 x CD3), a Tetra-Specific CD3-Engaging Darpin for the Treatment of Patients with Relapsed/Refractory AML or MDS/AML: Results of an Ongoing Phase 1/2a Study

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only